Citius Pharmaceuticals (CTXR) Q1 2026 earnings summary

Executive summary

• Achieved first commercial sales of LYMPHIR in December 2025, generating $3.94 million in net revenue for the quarter, with an 80% gross margin.

• Early physician adoption and nationwide product availability established, with patients receiving treatment at leading cancer centers.

• Commercial execution supported by an AI-enabled platform for targeted physician engagement in a rare oncology market.

• International access advancing through agreements for Named Patient Programs in Europe and the Middle East.

• Continued progress in late-stage pipeline assets, including Mino-Lok and Halo-Lido, with ongoing FDA engagement.

Financial highlights

• Net revenue for the quarter was $3.94 million, all from LYMPHIR sales, which began in December 2025.

• Gross profit was $3.15 million, representing an 80% gross margin.

• Net loss attributable to common stockholders was $8.2 million, or $0.38 per share, compared to $9.77 million, or $1.30 per share, in the prior year.

• Cash and cash equivalents stood at $7.7 million at quarter-end.

• Operating expenses totaled $12.17 million, up from $10.04 million in the prior year, mainly due to increased stock-based compensation.

Outlook and guidance

• Management anticipates increased revenues as LYMPHIR gains market acceptance and expands market penetration.

• Additional capital will be needed to support operations beyond May 2026; ongoing capital raising initiatives are in place.

• Sees growth opportunities from investigator-initiated studies, international expansion, and potential label extensions.

• Future growth depends on regulatory approval and commercialization of Mino-Lok and continued sales of LYMPHIR.